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British Journal of Haematology editorial comment 
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In this issue, Bhatia et al (2017) report a study from India in which iron deficiency anaemia was 
found to be resistant to oral iron therapy in over 10% of 550 young children: those resistant were 
subsequently investigated for the phenotype of Iron Refractory Iron Deficiency Anaemia (IRIDA) and, 
where this was present, whether TMPRSS6 gene variations might explain this finding. Their work 
draws attention to the approach to diagnosis of microcytic anaemias, and how new understanding of 
the molecular pathways involved in systemic and cellular iron metabolism (comprehensively 
reviewed by Hentze et al, 2010) may change this. 
Microcytic anaemias accompany reduced haemoglobin production in developing red cells.  This in 
turn results from failure of either haem synthesis (most commonly from lack of availability of iron 
but rarely from failure of protoporphyrin synthesis or of iron incorporation into the porphyrin ring in 
sideroblastic anaemias), or of globin synthesis in the thalassaemia disorders. Many young children 
have minimal or no iron stores as assessed by low serum ferritin concentrations and are at particular 
risk of developing iron deficiency anaemia, by far the commonest cause of childhood anaemia:  in 
the UK National Diet and Nutrition Surveys, up to a third of children aged 1.5 -4.5 years had serum 
ferritin values below WHO cut off values (Scientific Advisory Committee on Nutrition, 2010).  Iron 
deficiency in such children is usually the result of a combination of the increased iron requirements 
of growth and limited availability of iron in the diet, particularly if the latter is predominantly 
vegetarian, though chronic blood loss (e.g. from intestinal hookworm infestation) and exposure to 
cow’s milk may be important in many parts of the world. Chronic disease may also give rise to 
microcytic red cells as a result of iron malutilisation rather than any reduction in total body iron and 
may impair the response to iron therapy.  Contributions from multiple causes in a single patient may 
sometimes cause diagnostic difficulty, and interpretations of individual laboratory measures of iron 
status need to consider whether they are appropriate to the overall clinical context.  For example, a 
“normal” plasma ferritin in the presence of anaemia may be inappropriate in the sense that together 
the measures imply an overall reduction of total body iron, as may a “normal” plasma hepcidin in 
the presence of iron deficiency (Girelli et al, 2016).  
In most cases iron deficiency anaemia responds rapidly to oral iron, but less common alternative 
diagnoses must be considered, especially if there is an inadequate response.  Such refractoriness 
may result from failure of absorption: mucosal damage in coeliac disease has long been recognised 
as a potential cause for this, and more recently has been joined by Helicobacter pylori infection, at 
least in adults, where it is most probably the result of reduction in the gastric acid secretion needed 
to solubilise dietary iron (Hershko and Camaschella, 2014).  However, rarer inherited defects may 
lead to impaired iron availability or utilisation and inappropriately low amounts of iron absorption 
(Donker et al, 2014). Foremost among inherited defects leading to impaired iron absorption are 
those resulting in loss of function of the TMPRSS6 gene and of the ferroportin gene, SLC40A1, 
though the latter leads to macrophage iron retention and loading rather than a microcytic anaemia. 
TMPRSS6 codes for the serine protease, matriptase-2, which inhibits the transcription of hepcidin 
within hepatocytes.  Hepcidin is the major systemic regulator of internal iron exchange, 
downregulating iron release via the membrane transporter, ferroportin, from cells (enterocytes, 
macrophages and hepatocytes) that donate iron to circulating transferrin and thus make it available 
for incorporation into haemoglobin by developing erythroblasts (Hentze et al, 2010).  Matriptase-2 
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modulates hepcidin synthesis by interrupting the main iron-responsive signal transduction pathway. 
It cleaves the membrane protein haemojuvelin (HJV), one of several co-receptors, including 
transferrin receptor 2(TfR2) and HFE protein, for the bone morphogenetic protein (BMP) receptor.  
The BMP receptor complex initiates signal transduction after interaction with BMPs, particularly 
BMP-6:  the production of BMP-6 is regulated at mRNA level by iron (Meynard et al, 2009) and is 
therefore related to intracellular iron levels, particularly in liver non-parenchymal cells (Rausa et al, 
2015).  Diferric (iron saturated) transferrin stabilises TfR2 (Johnson & Enns, 2004), and by displacing 
of HFE from binding to transferrin receptor 1 makes HFE available to interact with the BMP receptor 
complex (Goswami & Andrews, 2006) , allowing hepcidin synthesis to be sensitive to circulating 
transferrin saturation.   While defects in HFE, HJV and TfR-2 underlie impaired hepcidin production 
and the development of haemochromatosis types 1,2 and 3, homozygous or double heterozygous 
defects in the TMPRSS6 gene lead to an enhanced hepcidin production that is inappropriate with 
respect to circulating transferrin saturation and to intracellular iron (as reflected by serum ferritin 
concentration). The resulting reduction in iron absorption and increased retention of iron within 
macrophages leads to the picture of IRIDA (Fineberg et al 2008).  
Bhatia et al (2017) restricted their analyses of TMPRSS6 to children whose phenotype included not 
only a sub-optimal response to oral iron (found in 60 of their patients), but also “normal” plasma 
ferritin concentrations, and plasma hepcidin concentrations that were inappropriately normal or 
high (a combination found in 23 of their patients).  As in several previous studies (e.g. Delbini et al, 
2010), they found many single nucleotide variations of TMPRSS6 including, in over half the children 
with this phenotype, multiple intronic variants (some known polymorphisms and some novel) that 
were potentially deleterious to mRNA synthesis.  These were sometimes also combined with exonic 
polymorphisms, including the common variant V737A associated with mildly reduced iron status (Nai 
et al, 2011). They suggest that such variations may cause or contribute to causation in rather more 
patients than might be expected from the relatively limited number of literature reports of IRIDA 
due to TMPRSS6 mutations.  However, their identification of the IRIDA phenotype depends on 
measuring an inappropriate hepcidin response and there is still much to do in developing a 
reproducible standardised assay that can be used in routine practice (Girelli et al 2016).  
Furthermore, many of the remaining children who were refractory to oral iron therapy and who did 
not meet the authors’ phenotypic criteria for IRIDA had unexplained inappropriate normal, or 
occasionally high, plasma hepcidin concentrations in the presence of a low plasma ferritin – it would 
be of considerable interest to study their TMPRSS6 genotypes, as well as those from control iron-
responsive patients, in order to better understand the clinical significance of the authors’ genetic 
findings.  The question of possible non-compliance with oral iron treatment in a paediatric 
population looms large, as well as whether hepcidin synthesis may have been stimulated by 
intercurrent childhood infection or more chronic diseases, which are not always associated with 
raised plasma C-reactive protein, e.g. in only some patients with intestinal hookworm  (Le et al, 
2007).  
Clearly, these findings are preliminary, but they add weight to the emerging picture of a complex 
interaction of TMPRSS6 variants with other physiological, dietary, and perhaps pathological factors, 
contributing to variably reduced iron absorption in what has been described as the “genotypically 
and phenotypically heterogenous” disease of IRIDA (Donker et al, 2016).  For the moment, however, 
the authors’ caution that investigation of other causes for failure to respond to oral iron should be 
undertaken before hepcidin assay or TMPRSS6 analysis, seems well-founded.   
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